阿帕替尼对卵巢癌术后复发铂类耐药的影响  

Effect of apatinib on platinum resistance in patients with ovarian cancer after recurrence

作　　者：郭军[1] 刘登湘[1] 王娜[1] 孙雅薇 何莉莉[1] 朱晓燕[1] 郭治[1] 王利飞 GUO Jun;LIU Dengxiang;WANG Na;SUN Yawei;HE Lili;ZHU Xiaoyan;GUO Zhi;WANG Lifei(Department of Medical Oncology,Xingtai People's Hospital,Xingtai,Xingtai,Hebei 054031,China;Department of Gynaecology,Xingtai People's Hospital,Xingtai,Xingtai,Hebei 054031,China)

机构地区：[1]邢台市人民医院肿瘤内科,河北邢台054031 [2]邢台市人民医院妇科,河北邢台054031

出　　处：《安徽医药》2022年第3期603-606,共4页Anhui Medical and Pharmaceutical Journal

基　　金：河北省医学科学研究重点课题计划(20181617)。

摘　　要：目的探讨阿帕替尼治疗卵巢癌术后复发铂类耐药的临床价值。方法选择2017年10月至2019年3月期间邢台市人民医院66例卵巢癌术后复发铂类耐药的病人作为研究对象,采用随机数字表法分为阿帕替尼联合化疗组、化疗组及阿帕替尼单药组,各22例。其中联合化疗组给予阿帕替尼+多西他赛(或吉西他滨)治疗,4个周期后阿帕替尼单药维持;化疗组给予多西他赛(或吉西他滨)治疗;单药组给予单独阿帕替尼治疗。4周为1个周期,本研究开始服药即开始随访。比较三组病人的疗效,并比较无进展生存期(PFS)、客观缓解率(ORR)、疾病控制率(DCR)、总生存期(OS)以及不良反应发生率。结果三组病人ORR及DCR比较差异有统计学意义(P<0.05);两两比较:联合化疗组ORR及DCR均高于化疗组与单药组(P<0.05);单药组DCR高于化疗组(P<0.05);单药组ORR与化疗组比较差异无统计学意义(P>0.05)。联合化疗组中位PFS为8.8(7.9~9.6)个月,化疗组中位PFS为5.9(5.1~6.8)个月,单药组中位PFS为7.1(6.7~7.6)个月,联合化疗组疾病进展风险显著低于化疗组及单药组(P<0.05),单药组疾病进展风险显著低于化疗组(P<0.05)。联合化疗组中位OS为9.0(8.6~9.3)个月,化疗组中位OS为6.0(4.3~7.6)个月,单药组中位OS为7.0(6.2~7.7)个月,联合化疗组疾病死亡风险显著低于化疗组及单药组(P<0.05),单药组疾病死亡风险显著低于化疗组(P<0.05)。三组不良反应总发生率比较差异无统计学意义(P>0.05)。结论阿帕替尼联合化疗治疗卵巢癌术后复发铂类耐药明显提高了ORR及DCR,明显延长病人生存时间,且未增加不良反应程度,病人可耐受,对卵巢癌术后复发铂类耐药治疗有重要临床意义。Objective To explore the clinical value of apatinib in the treatment of postoperative recurrence of ovarian cancer with platinum resistance.Methods From October 2017 to March 2019,66 patients with platinum-resistant ovarian cancer after surgery in Xingtai People's Hospital were selected as the research subjects,and they were divided into apatinib combined chemotherapy group,chemotherapy group and apatinib single-agent group with 22 cases in each group,by the random number table method.Among them,the combined chemotherapy group was given apatinib+docetaxel(or gemcitabine)treatment and apatinib single-agent maintenance af⁃ter 4 cycles;the chemotherapy group was given docetaxel(or gemcitabine)treatment;and the single-agent group was given apatinib alone.Every 4 weeks is a cycle,and the follow-up starts immediately after taking the drug in this study.The efficacy of the three groups of patients was compared,and the progression-free survival(PFS),objective response rate(ORR),disease control rate(DCR),overall survival(OS),and incidence of adverse reactions were compared.Results There were significant differences in ORR and DCR among the three groups(P<0.05);pairwise comparison:ORR and DCR in the combined chemotherapy group were higher than those in the che⁃motherapy group and the single-agent group(P<0.05);the DCR of the single-agent group was higher than of the chemotherapy group(P<0.05);there was no significant difference in ORR between the single-agent group and the chemotherapy group(P>0.05).The median PFS of the combined chemotherapy group was 8.8(7.9-9.6)months,the median PFS of the chemotherapy group was 5.9(5.1-6.8)months,and the median PFS of the single-agent group was 7.1(6.7-7.6)months.The risk of disease progression in the combined chemo⁃therapy group was significantly lower than that in the chemotherapy group and the single-agent group(P<0.05),and the risk of disease progression in the single-agent group was significantly lower than that in the chemotherapy group(P<0.05).The median OS of the com⁃bi

关 键 词：卵巢肿瘤 阿帕替尼 抗药性 肿瘤 复发 铂类耐药 

分 类 号：R737.31[医药卫生—肿瘤]